<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT201202218629N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2013-03-27</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Treatment of Swallowing disorders in stroke patients</public_title>
      <acronym>TDT TMS</acronym>
      <scientific_title>Comparative Study of effectiveness of Combined treatment  of dysphagia(Traditional Dysphagia Therapy &amp;Transcranial Magnetic Stimulation)  and other two treatments in Stroke Patients".</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2012-06-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>15</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/9123</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Dysphagia.</hc_freetext>
      <i_freetext>Intervention 1: Control Group : The first group are provided traditional dysphagia therapy. this protocol is included competional treatments , postural changes, oromotor exercies and swallowind manuers. this treatments is provided in 30 min for 3 days of week and for 6  weeks. Intervention 2: Intervention Group : The second group are provided inhibitory  Repatative Transcranial Magnetic Stimulations (rTMS) in healty hemisphere. Stimulations were performed at 1 Hz for 20 min at 20% above the threshold value. It was repeate each day for 5 days.&#13;
All stimulations were carried out using a Magstim superrapi stimulator (Magstim, Whitland, Dyfed, UK) equipped with a air-refreshed, double, 70-mm, figure-of-eight coil (peak magnetic field = 2 T), at the maximal output of the stimula. The vertex of the cranium was first identified. The coil was then positioned 2–4 cm anteriorlyand 4–6 cm laterally and moved around in this area to obtain the highest electromyographic mylohyoid response. Intervention 3: Intervention Group:&#13;
The third group is given combined treatment(TDT and rTMS). Firstly patients are given rTMS for 5 day and Simultaneously are given TDT for 3days in week for 6 weeks. In every day that is provided two treatment Simultaneously patients are given rTMS for 20 min and after short rest (5-10 min) another treatment (TDT) is provided for 30 min by speech&amp; language Pathologist.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Leila Ghelichi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Speech therapy Department, Rehabilitation School, Shahnazari Street, Madar Squre, Mirdamad</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 2222 8051</telephone>
        <email>l-ghelichi@razi.tums.ac.ir ,lghelichi@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Leila Ghelichi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Speech therapy Department, Rehabilitation School, Shahnazari Street, Madar Squre, Mirdamad</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 2222 8051</telephone>
        <email>l-ghelichi@razi.tums.ac.ir ,lghelichi@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion Criteria:&#13;
 1-Subacute(at least one week  after the accuring of stroke) Stroke&#13;
 patient with dysphagia&#13;
 2-Patients' rang of age is between 20-80&#13;
 3-Patients from Both gender&#13;
 4-Suffering from dysphagia and aspiration diagnosed by MASA(Mann&#13;
 Assessment of  Swallowing Ability)&#13;
 5- they have not received any Dysphagia therapy.&#13;
 Exclusion Criteria:&#13;
 1- Dementia and Alzheimer and dysphagia due to other neurogenic Disease&#13;
 2_ Significant reflux&#13;
3- Severe Aphasia&#13;
 4_ Dysphagia due to drug toxicity&#13;
5- severe Reflux&#13;
 6_ Agitation, with decreased level of consciousness, or otherwise&#13;
 noncompliant&#13;
 7_ Pregnancy</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>80 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>R13</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Difficulty in swallowing</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Control Group : The first group are provided traditional dysphagia therapy. this protocol is included competional treatments , postural changes, oromotor exercies and swallowind manuers. this treatments is provided in 30 min for 3 days of week and for 6  weeks.</i_keyword>
      <i_keyword>Intervention Group : The second group are provided inhibitory  Repatative Transcranial Magnetic Stimulations (rTMS) in healty hemisphere. Stimulations were performed at 1 Hz for 20 min at 20% above the threshold value. It was repeate each day for 5 days.&#13;
All stimulations were carried out using a Magstim superrapi stimulator (Magstim, Whitland, Dyfed, UK) equipped with a air-refreshed, double, 70-mm, figure-of-eight coil (peak magnetic field = 2 T), at the maximal output of the stimula. The vertex of the cranium was first identified. The coil was then positioned 2–4 cm anteriorlyand 4–6 cm laterally and moved around in this area to obtain the highest electromyographic mylohyoid response.</i_keyword>
      <i_keyword>Intervention Group:&#13;
The third group is given combined treatment(TDT and rTMS). Firstly patients are given rTMS for 5 day and Simultaneously are given TDT for 3days in week for 6 weeks. In every day that is provided two treatment Simultaneously patients are given rTMS for 20 min and after short rest (5-10 min) another treatment (TDT) is provided for 30 min by speech&amp; language Pathologist</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Score of MASA test. Timepoint: Before treatment,5th session,10th session,the end of forth week of treatment and the end of sixth week of treatment. Method of measurement: MASA test.</prim_outcome>
      <prim_outcome>Dysphagia. Timepoint: Before treatment,5th session,10th session,the end of forth week of treatment and the end of sixth week of treatment. Method of measurement: MASA test.</prim_outcome>
      <prim_outcome>Severity of Dysphagia. Timepoint: Before treatment,5th session,10th session,the end of forth week of treatment and the end of sixth week of treatment. Method of measurement: MASA test.</prim_outcome>
      <prim_outcome>Aspiration. Timepoint: Before treatment,5th session,10th session,the end of forth week of treatment and the end of sixth week of treatment. Method of measurement: MASA test.</prim_outcome>
      <prim_outcome>Severity of Aspiration. Timepoint: Before treatment,5th session,10th session,the end of forth week of treatment and the end of sixth week of treatment. Method of measurement: MASA test.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2012-12-26</approval_date>
        <contact_name>Tehran University of Medical Sciences</contact_name>
        <contact_address>Sixth floor, Center building of University, Qods street, Keshavarz Blvd Tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
